Aardvark Therapeutics, Inc.
AARDNasdaqCIK 1774857HealthcareFiscal year ends Dec 31
Latest reported revenue, Q2 FY2026$0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344987. Derived: 6-month figure less the 3-month figure.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 11, 2026.Latest quarter: Q2 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenue$0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344987. Derived: 6-month figure less the 3-month figure.Report this figureSign changed from a year earlier - Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Diluted EPS−$0.66Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.66 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344987.Report this figure+0.0% on a year earlier - Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | period not labelled2024-09-30 | period not labelled2024-12-31 | Q1 FY20252025-03-31 | Q2 FY20252025-06-30 | Q3 FY20252025-09-30 | Q4 FY20252025-12-31 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $m | not reported (Revenue not reported) | not reported (Revenue not reported) | 0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-05-14, accession 0000950170-25-071560.Report this figure | 0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-13, accession 0000950170-25-108116. Derived: 6-month figure less the 3-month figure.Report this figure | 0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001193125-25-280260. Derived: 9-month figure less the 6-month figure.Report this figure | 0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119770. Derived: 12-month figure less the 9-month figure.Report this figure | 0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-210675.Report this figure | 0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344987. Derived: 6-month figure less the 3-month figure.Report this figure | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Diluted EPS | $ per share | (1.05)Diluted EPS, period not labelled, three months to 2024-09-30−$1.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001193125-25-280260.Report this figure | not reported (Diluted EPS not reported) | (0.71)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-210675.Report this figure | (0.66)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344987.Report this figure | (0.75)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001193125-25-280260.Report this figure | not reported (Diluted EPS not reported) | (0.99)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.99 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-210675.Report this figure | (0.66)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344987.Report this figure | |
| Free cash flow | $m | (4.0)Free cash flow, period not labelled, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001193125-25-280260. Derived: 9-month figure less the 6-month figure.Capital expenditure: $5.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001193125-25-280260. Derived: 9-month figure less the 6-month figure.Report this figure | (7.7)Free cash flow, period not labelled, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$7.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-23, accession 0001193125-26-119770. Derived: 12-month figure less the 9-month figure.Capital expenditure: $6.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-23, accession 0001193125-26-119770. Derived: 12-month figure less the 9-month figure.Report this figure | (11.4)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$11.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-210675.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-14, accession 0000950170-25-071560.Report this figure | (9.9)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$9.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344987. Derived: 6-month figure less the 3-month figure.Capital expenditure: $91.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344987. Derived: 6-month figure less the 3-month figure.Report this figure | (16.1)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$16.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001193125-25-280260. Derived: 9-month figure less the 6-month figure.Capital expenditure: $4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001193125-25-280260. Derived: 9-month figure less the 6-month figure.Report this figure | (16.8)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$16.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-23, accession 0001193125-26-119770. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-23, accession 0001193125-26-119770. Derived: 12-month figure less the 9-month figure.Report this figure | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY2024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|
| Revenue | $m | not reported (Revenue not reported) | 0.0Revenue, FY2025, twelve months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-23, accession 0001193125-26-119770.Report this figure | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue of zero not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue of zero not reported) | |
| Diluted EPS | $ per share | (5.15)Diluted EPS, period not labelled, twelve months to 2024-12-31−$5.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-23, accession 0001193125-26-119770.Report this figure | (2.93)Diluted EPS, FY2025, twelve months to 2025-12-31−$2.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-23, accession 0001193125-26-119770.Report this figure | |
| Free cash flow | $m | (18.2)Free cash flow, period not labelled, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$18.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-23, accession 0001193125-26-119770.Capital expenditure: $109.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-23, accession 0001193125-26-119770.Report this figure | (54.3)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$54.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-23, accession 0001193125-26-119770.Capital expenditure: $95.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-23, accession 0001193125-26-119770.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Decheng Capital LLC | 2026-06-30 | $22.6m | 3,917,299 | Unchanged | |
| CITADEL ADVISORS LLC | 2026-06-30 | $7.4m | 1,283,166 | Added+40,389 | |
| Laurion Capital Management LP | 2026-06-30 | $6.0m | 1,034,459 | Unchanged | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $3.2m | 562,877 | Added+8,776 | |
| AQR CAPITAL MANAGEMENT LLC | 2026-06-30 | $2.8m | 480,249 | Added+345,754 | |
| EcoR1 Capital, LLC | 2026-06-30 | $2.3m | 396,194 | New+396,194 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2026-06-30 | $1.7m | 300,000 | Unchanged | |
| BlackRock, Inc. | 2026-06-30 | $1.1m | 187,045 | Reduced−605,526 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-06-30 | $863.5k | 149,844 | Reduced−159,605 | |
| CANTOR FITZGERALD, L. P. | 2026-06-30 | $671.5k | 116,582 | Added+49,900 |
Recent filings
All 114 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2312:38 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429509 |
| 2026-10-2220:17 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-428943 |
| 2026-10-0820:14 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-417935 |
| 2026-08-1720:10 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-354053 |
| 2026-08-1121:09 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344987 |
| 2026-08-1121:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344978 |
| 2026-07-1020:05 ET | DEF 14A | Proxy statementPeriod 2026-08-14 | 0001193125-26-300874 |
| 2026-06-1220:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-269377 |
| 2026-05-1420:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-224069 |
| 2026-05-0713:32 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-210675 |
Latest annual report
Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 23, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter
About the filer
- CIK
- 1774857
- Tickers
- AARD
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- DE
- Filer category
- <br>Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.